加载中
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
收盘时
US$6.54
−US$0.04 · -0.61%
盘后
US$6.51
−US$0.03 · -0.46%
10月12日 19:39 ET
盘中时间采用ET。市场数据可能有所延迟。
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
日内区间
当前US$6.54
52周区间
当前US$6.54
盘中时间采用ET。市场数据可能有所延迟。
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
日内区间
当前US$6.54
52周区间
当前US$6.54
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 4.94万 USD | 5.11万 USD | 5.74万 USD | 11.96万 USD | 2527 USD |
| 毛利 | −4.94万 USD | −5.11万 USD | −5.74万 USD | −11.96万 USD | −2527 USD |
| 研究与开发 | 204.54万 USD | 137.18万 USD | 153.12万 USD | 441.52万 USD | 63.54万 USD |
| 销售、一般及管理费用 | 357.19万 USD | 432.2万 USD | 470.62万 USD | 446.71万 USD | 297.53万 USD |
| 营业费用 | 561.73万 USD | 569.38万 USD | 623.74万 USD | 888.24万 USD | 361.07万 USD |
| 利息收入 | 13.29万 USD | 27.12万 USD | 5.91万 USD | — | — |
| 利息支出 | 1.95万 USD | 3.62万 USD | — | 2.08万 USD | — |
| 折旧和摊销 | 4.94万 USD | 5.11万 USD | 5.75万 USD | 11.3万 USD | 2514.9 USD |
| 营业利润 | −566.67万 USD | −574.49万 USD | −629.48万 USD | −900.2万 USD | −361.32万 USD |
| 净利润 | −385.66万 USD | −525.47万 USD | −860.91万 USD | −992.85万 USD | −365.6万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
